CKII-Phosphorylated HPV-16 E7 Disrupts Planar Cell Polarity by Recruiting Vangl1

This study reveals that CKII-phosphorylated HPV-16 E7 oncoprotein drives cervical cancer invasion by recruiting and disrupting the homeostasis of the planar cell polarity protein Vangl1, thereby remodeling tissue polarity and enhancing tumor aggressiveness.

The Gist

The Big Picture: A Viral Hijacker and a Broken Compass

Imagine a city (your body) where every building (cell) has a strict set of rules to stay upright and organized. These rules are managed by a "City Planning Department" called Planar Cell Polarity (PCP). One of the most important foremen in this department is a protein called Vangl1. Its job is to make sure cells know which way is "up," which way is "down," and how to line up neatly to form strong tissues.

Now, imagine a criminal mastermind: the HPV-16 virus. This virus is notorious for causing cervical cancer. It has a secret weapon, a protein called E7. Usually, we know E7 breaks the "brakes" of the cell cycle (making cells divide uncontrollably), but this paper reveals a new, sneaky trick: E7 doesn't just break the brakes; it steals the City Foreman's compass.

The Story in Four Acts

1. The Pickpocket (The Discovery)

The researchers found that the viral protein E7 is a master pickpocket. But it's picky about who it steals from.

• The Clue: E7 has a special "badge" on it (a phosphate tag) that only appears when a specific enzyme (CKII) adds it.
• The Heist: Once E7 has this badge, it specifically targets Vangl1. It ignores other similar proteins (like Vangl2) and doesn't bother with low-risk viruses. It's like a thief who only steals from the most valuable vaults.
• The Result: E7 grabs Vangl1 and holds onto it tightly.

2. The Double-Edged Sword (The Stabilization)

Usually, when a cell has too much of a protein, it throws it in the trash (degradation). But E7 is clever.

• The Trap: When E7 grabs Vangl1, it acts like a bodyguard. It stops the cell from throwing Vangl1 away.
• The Twist: In a strange twist of fate, Vangl1 also acts as a bodyguard for E7. They hold onto each other.
• The Analogy: Imagine two people, a criminal (E7) and a police officer (Vangl1). Instead of arresting each other, they get handcuffed together. The criminal can't be caught because the officer is protecting him, and the officer can't leave because the criminal won't let go. Both become "stuck" and stay around much longer than they should. This creates a chaotic, unstable environment inside the cell.

3. The Traffic Jam (The Mislocalization)

In a healthy cell, Vangl1 is like a traffic cop standing at the edge of the cell (the membrane), directing traffic so cells move in a coordinated line.

• The Hijack: E7 drags Vangl1 away from the edge and dumps it into the middle of the cell (the cytoplasm).
• The Mechanism: E7 does this by hijacking a delivery truck called AP1M1. This truck is supposed to deliver Vangl1 to the cell's edge. E7 steals the truck, so Vangl1 gets lost in the warehouse instead of reaching the street.
• The Consequence: Without Vangl1 at the edge, the cells lose their sense of direction. They stop lining up and start getting messy.

4. The Chaos in the City (The Cancer Invasion)

What happens when the City Foreman is lost and the traffic cops are gone? The city falls apart.

• Spheroids (Mini Tumors): The researchers grew tiny 3D balls of cancer cells (spheroids).
  • Normal Cancer Cells: They form tight, round balls and then send out organized "fingers" to invade new territory (metastasis).
  • Without Vangl1: When the researchers removed Vangl1, the balls fell apart. They became messy, frayed, and couldn't invade effectively.
• The "Super-Drug" Effect: Here is the hopeful part. Because the cancer cells are so dependent on this broken system (E7 holding onto Vangl1), they become fragile.
  • When the researchers treated these cells with standard chemotherapy drugs, the cells that had lost Vangl1 died much faster than the healthy ones.
  • Analogy: It's like a house built on a shaky foundation. If you push it slightly (chemotherapy), it collapses. A house built on solid ground (normal cells) just wobbles.

Why This Matters

This paper changes how we see cervical cancer.

1. It's not just about cell division: We knew HPV made cells divide too fast. Now we know it also messes up the cell's "compass" and "architecture."
2. Vangl1 is a new target: Since the cancer cells rely on this broken E7-Vangl1 relationship to survive and invade, targeting Vangl1 (or the delivery truck AP1M1) could be a new way to treat the disease.
3. Sensitivity to drugs: If we can disrupt this relationship, we might make existing chemotherapy drugs work much better.

The Bottom Line

The HPV virus uses a "sticky" trick to hijack a cell's navigation system (Vangl1). This keeps the virus and the navigation protein stuck together, causing the cell to lose its shape and become invasive. However, this very trick makes the cancer cell fragile. If we can break the handcuffs between the virus and the navigation protein, the cancer city collapses, and the drugs can finish the job.

Technical Summary

1. Problem Statement

High-risk Human Papillomaviruses (HPVs), particularly HPV-16 and HPV-18, are the primary etiological agents of cervical cancer. Their oncogenicity relies on the continuous expression of the E6 and E7 oncoproteins. While the canonical mechanism of E7 involves inactivating the retinoblastoma protein (pRB) to drive cell cycle progression, the molecular mechanisms by which E7 promotes aggressive invasion, metastasis, and the disruption of tissue architecture (specifically Planar Cell Polarity or PCP) remain incompletely understood. The study aims to identify novel phosphorylation-dependent interactors of HPV-16 E7 that drive malignant transformation and invasive phenotypes in cervical cancer.

2. Methodology

The researchers employed a multi-faceted approach combining proteomics, biochemistry, cell biology, and 3D modeling:

• Proteomic Screening: Biotin-tagged peptides corresponding to the CKII phosphorylation site (CR2 region) of HPV-16 E7 (phosphorylated vs. non-phosphorylated) were used as bait in streptavidin pulldown assays with HaCaT keratinocyte lysates, followed by mass spectrometry to identify binding partners.
• Biochemical Validation:
  • GST Pulldowns: Used to test interactions between endogenous Vangl1 and various E7 variants (HPV-16, -18, -11, -5; phosphorylated vs. non-phosphorylated; N-terminal vs. C-terminal).
  • Co-immunoprecipitation (Co-IP): Performed in HEK293 cells to validate physical interactions between FLAG-tagged Vangl1 and HA/FLAG-tagged E7.
  • Pharmacological Inhibition: Treatment with the CKII inhibitor (CX-4945) to confirm the dependency of the interaction on phosphorylation.
  • Peptide Mutagenesis: Comparison of wild-type phosphorylated peptides, non-phosphorylated peptides, and phosphomimic (Serine-to-Aspartic acid) peptides to determine if charge alone or true phosphorylation drives binding.
• Cellular Analysis:
  • Knockdown Studies: siRNA-mediated depletion of E6/E7 or Vangl1 in HPV-positive (CaSki, HeLa) and HPV-negative (C-33A, HaCaT) cell lines.
  • Protein Stability Assays: Cycloheximide chase assays to measure protein half-lives; treatment with proteasome (MG132) and lysosome (Chloroquine) inhibitors to determine degradation pathways.
  • Subcellular Fractionation: Separation of cytosolic, membrane, and cytoskeletal fractions to track Vangl1 localization.
  • Immunofluorescence: Confocal microscopy to visualize Vangl1 and E7 localization and co-localization in 2D and 3D contexts.
• Functional Assays:
  • 3D Spheroid Models: Generation of CaSki spheroids to assess architectural integrity and collective invasion in Matrigel/Collagen matrices of varying stiffness.
  • Invasion Assays: 2D Matrigel invasion and 3D collagen invasion assays to quantify invasive capacity.
  • Chemosensitivity: Treatment of spheroids with Palbociclib, Cisplatin, and Etoposide to assess therapeutic response following Vangl1 or E6/E7 depletion.

3. Key Contributions and Results

A. Identification of Vangl1 as a Phosphorylation-Dependent Interactor

• Mass spectrometry identified Vangl1 (a core PCP scaffold protein) as a novel interactor specifically enriched by phosphorylated HPV-16 E7.
• Specificity: The interaction is highly selective:
  • Strong binding to phosphorylated HPV-16 E7.
  • Weak/undetectable binding to HPV-18 E7 (phosphorylated), HPV-11 E7, HPV-5 E7, or non-phosphorylated HPV-16 E7.
  • Paralog specificity: E7 binds Vangl1 robustly but shows minimal interaction with Vangl2.
• Mechanism: The interaction requires true CKII-mediated phosphorylation at serines 31/32/33. Phosphomimic peptides (S-to-D substitution) failed to bind, indicating that the structural conformation induced by phosphorylation, not just negative charge, is critical.

B. Reciprocal Stabilization and Proteostatic Imbalance

• Aberrant Retention: In HPV-positive cells, E7 expression leads to a "biphasic" proteostatic imbalance. While unphosphorylated Vangl1 is degraded, phosphorylated Vangl1 is aberrantly retained and stabilized.
• Reciprocal Stabilization: Co-expression of E7 and Vangl1 results in a mutual increase in protein half-life. E7 stabilizes phosphorylated Vangl1, and conversely, Vangl1 stabilizes E7 (E7 half-life increases from ~1.2h to ~2.2h when Vangl1 is present).
• Degradation Pathways: The stabilization is not solely due to the inhibition of canonical proteasomal or lysosomal degradation but involves a non-canonical mechanism linked to mislocalization.

C. Hijacking of Trafficking via AP1M1

• Mechanism of Mislocalization: E7 co-opts the clathrin adaptor subunit AP1M1 (part of the AP-1 complex).
• Interaction: Phosphorylated E7 binds AP1M1.
• Consequence: In the presence of E7, Vangl1 is sequestered away from the cell cortex (where it normally functions) and accumulates in the cytoplasm and cytoskeletal fractions. Depletion of AP1M1 mimics the effects of E6/E7 knockdown, restoring Vangl1 trafficking and reducing E7 levels, confirming AP1M1 is the trafficking node hijacked by E7.

D. Functional Impact on Architecture and Invasion

• Spheroid Integrity: In 3D CaSki spheroids, depletion of E6/E7 or Vangl1 leads to severe structural disintegration, loss of cohesion, and fragmented contours, indicating Vangl1 is a critical downstream effector of E7 for maintaining epithelial architecture.
• Collective Invasion:
  • Control spheroids exhibit organized, finger-like collective invasion into collagen matrices.
  • Vangl1 Depletion: Abolishes collective invasion. Spheroids fail to form protrusions, showing instead shape distension or mono-directional, non-cohesive invasion.
  • Localization: In invading spheroids, Vangl1 is enriched at the leading edge of migrating cells, establishing front-rear polarity. This enrichment is lost upon Vangl1 knockdown.
• Chemosensitivity: Depletion of Vangl1 (or E6/E7) significantly enhances the sensitivity of cervical cancer spheroids to chemotherapeutics (Palbociclib, Cisplatin, Etoposide), causing rapid dissociation and cell death compared to controls.

4. Significance

• Novel Mechanism of Oncogenesis: The study uncovers a new mechanism by which HPV-16 E7 drives malignancy: by recruiting and stabilizing Vangl1 via CKII phosphorylation, thereby hijacking the Planar Cell Polarity (PCP) pathway.
• Link to Metastasis: It establishes Vangl1 as a central effector in the collective invasion of cervical cancer cells, explaining how HPV infection promotes the transition from localized lesions to invasive carcinoma.
• Therapeutic Implications:
  • The study identifies Vangl1 and the E7-AP1M1-Vangl1 axis as potential therapeutic targets.
  • Targeting Vangl1 or disrupting the E7-Vangl1 interaction could restore normal polarity, inhibit collective invasion, and sensitize HPV-positive tumors to existing chemotherapies.
• Specificity: The findings highlight that the oncogenic potential of high-risk HPV subtypes (like HPV-16) may be partly due to their unique ability to engage specific host polarity scaffolds (Vangl1) in a phosphorylation-dependent manner, distinguishing them from low-risk or less oncogenic subtypes.

In conclusion, the paper demonstrates that CKII-phosphorylated HPV-16 E7 acts as a molecular "hijacker" of Vangl1 trafficking, creating a reciprocal stabilization loop that disrupts cell polarity, drives collective invasion, and confers chemoresistance in cervical cancer.